等待開盤 07-23 09:30:00 美东时间
-0.080
-4.79%
Imunon Inc. (NASDAQ:IMNN) on Tuesday reported new preliminary findings from its ongoing Phase 2 minimal residual disease (MRD) translational trial. MRD refers to the small number of cancer cells that remain in the body during or after treatment. The data showed that patients receiving IMNN-001 along...
07-21 20:30
IMUNON, Inc. (NASDAQ:IMNN), a clinical-stage company in Phase 3 development with its DNA-mediated immunotherapy, today announced that the independent Data Monitoring Committee (iDMC) has recommended continuation of the pivotal Phase 3 OVATION 3 clinical trial evaluating IMNN-001 in combination with ...
06-23 20:03
Includes up-front issuance of preferred stock for $2.5 million and secured promissory notes for $7.72 millionUniquely structured, flexible financing supports IMUNON's Highly Anticipated Phase 3 OVATION 3 Study of
06-04 20:04
Imunon (NASDAQ:IMNN) released first-quarter financial results and hosted an ear...
05-12 23:54
Imunon (NASDAQ:IMNN) reported quarterly losses of $(0.84) per share which beat the analyst consensus estimate of $(1.07) by 21.5 percent. This is a 73.33 percent increase over losses of $(3.15) per share from the same
05-12 20:01
Companies Reporting Before The Bell • Sionna Therapeutics (NASDAQ:SION) is proj...
05-12 19:11
今日重点评级关注:Guggenheim:维持AtaiBeckley Inc."买入"评级,目标价从11美元升至16美元;RBC Capital:维持MeiraGTx Holdings"跑赢大市"评级,目标价从16美元升至24美元
04-20 11:33
Maxim Group analyst Jason McCarthy initiates coverage on Imunon (NASDAQ:IMNN) with a Buy rating and announces Price Target of $10.
04-17 21:18
Imunon (NASDAQ:IMNN) reported quarterly losses of $(1.30) per share which missed the analyst consensus estimate of $(1.13) by 15.04 percent. This is a 56.67 percent increase over losses of $(3.00) per share from the same
03-31 20:12
Companies Reporting Before The Bell • Bitfarms (NASDAQ:BITF) is projected to re...
03-31 19:11